연구동향 분석

Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-analysis from Randomized Clinical Trials and Propensity Score Matching of Multicentre Cohort Study

Wei Ren Yunfang Yu Huangming Hong Ying Wang Quanlong Gao Yongjian Chen Peixian Chen Jianli Zhao Qiyun Ou Dagui Lin Tuping Fu Yujie Tan Chenchen Li Xinxin Xie Guolin Ye Jun Tang Herui Yao 2022년

논문상세정보
인용/피인용
' Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-analysis from Randomized Clinical Trials and Propensity Score Matching of Multicentre Cohort Study' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Progression-free survival
  • Endocrine therapy
  • Metastatic breast neoplasms
  • chemotherapy
  • overall survival
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
399 0

0.0%

' Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-analysis from Randomized Clinical Trials and Propensity Score Matching of Multicentre Cohort Study' 의 참고문헌

  • Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer
  • Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
    Yu YF [2018]
  • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions : explanation and elaboration
  • Propensity score estimation: neural networks, support vector machines, decision trees (CART), and meta-classifiers as alternatives to logistic regression
  • Prognostic immune-related gene models for breast cancer : a pooled analysis
    Zhao J [2017]
  • Phase III, multicenter, randomized trial of maintenance chemothe-rapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy : KCSG-BR07-02
    Park YH [2013]
  • New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)
  • Meta-analysis in clinical trials
  • Measuring inconsistency in meta-analyses
    Higgins JP [2003]
  • Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer : GEICAM 2001-01 study
    Alba E [2010]
  • Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer(IMELDA) : a randomised, open-label, phase 3 trial
    Gligorov J [2014]
  • Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer
    Gennari A [2006]
  • Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association
    Muss HB [1991]
  • Improving the quality of life during chemotherapy for advanced breast cancer : a comparison of intermittent and continuous treatment strategies
    Coates A [1987]
  • GRADE : an emerging consensus on rating quality of evidence and strength of recommendations
    Guyatt GH [2008]
  • Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer
  • Essen Breast Cancer Study Group
    Kloke O [1999]
  • Epirubicin-based chemotherapy in metastatic breast cancer patients : role of dose-intensity and duration of treatment
  • Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients
    Jacquet E [2018]
  • Efficacy and safety of cyclin-dependent kinases 4 and 6 inhibitors in HR+/HER2-advanced breast cancer
    Xie N [2020]
  • Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment
    Falkson G [1998]
  • Duration of chemotherapy for metastatic breast cancer : a systematic review and meta-analysis of randomized clinical trials
    Gennari A [2011]
  • Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months
    Ejlertsen B [1993]
  • Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists’ preferences
    Nooij MA [2003]
  • Comparison of short-term and continuous chemotherapy(mitozantrone)for advanced breast cancer
    Harris AL [1990]
  • Cochrane handbook for systematic reviews of iterventions, version 5.1.0
    Higgins JP [2011]
  • Association of long noncoding RNA biomarkers with clinical immune subtype and prediction of immunotherapy response in patients with cancer
    Yu Y [2020]
  • A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast
    Gregory RK [1997]
  • A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab : a GINECO group study
    Tredan O [2016]
  • A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer
    Kwan TT [2018]